Document:

Exhibit 10.13(a)

 

CARDCONNECT
CORP.

2016 OMNIBUS
EQUITY COMPENSATION PLAN

July 27,
2016

	1.		Purpose

The
purpose of the Plan is to provide (i) employees of the Company or an Affiliate of the Company, (ii) any individual who
provides services to the Company or an Affiliate of the Company, and (iii) members of the Board, with the opportunity to receive
grants of Options, SARs, Stock Units, Performance Shares, Stock Awards, Dividend Equivalents and Other Stock-Based Awards. The
Company believes that the Plan will encourage the Participants to contribute materially to the growth of the Company, thereby benefiting
the Company’s stockholders, and will align the economic interests of the Participants with those of the stockholders. The
Plan is dated as of July 27, 2016, subject to stockholder approval of the Plan.

 

	2.		Definitions

 

Whenever
used in this Plan, the following terms will have the respective meanings set forth below:

(a) “Administrator” means
the Committee and any delegate of the Committee that is appointed in accordance with Section 3, except that the Board shall
be the Administrator with respect to Grants to Non-Employee Directors.

(b) “Affiliate” means
a person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control
with, the Person specified.

(c) “Board” means
the Company’s Board of Directors as constituted from time to time.

(d) “Change
of Control” means the first to occur of any of the following events:

(i)
the sale, lease or transfer, in one or a series of related transactions, of all or substantially all of the assets of the Company,
taken as a whole, to any Person other than any one or more Qualified Affiliates;

(ii)
the acquisition by any Person or group (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Exchange
Act, or any successor provision), including any group acting for the purpose of acquiring, holding or disposing of securities (within
the meaning of Rule 13d-5(b)(1) under the Exchange Act), in a single transaction or in a related series of transactions, by
way of merger, consolidation or other business combination or purchase of beneficial ownership (within the meaning of Rule 13d-3
under the Exchange Act, or any successor provision) of 50% or more of the total voting power of the voting capital interests
of the Company, other than an acquisition by one or more Qualified Affiliates; or

(iii)
directors are elected such that a majority of the members of the Board shall have been members of the Board for less than two years,
unless the election or nomination for election of each new director who was not a director at the beginning of such two-year period
was approved by a vote of at least two-thirds of the directors then still in office who were directors at the beginning of such
period.

 

(e) “Code” means
the Internal Revenue Code of 1986, as amended.

(f) “Company” means
CardConnect Corp., a Delaware corporation, formerly known as FinTech Acquisition Corp.

(g) “Committee” means
the Compensation Committee of the Board or another committee appointed by the Board to administer the Plan.

(h) “Date
of Grant” means the date a Grant is effective; provided, however, that no retroactive Grants will be made.

(i) “Dividend
Equivalent” means an amount determined by multiplying the number of shares of Stock, Performance Shares or Stock
Units subject to a Grant by the per-share cash dividend, or the per-share fair market value (as determined by the Administrator)
of any dividend in consideration other than cash, paid by the Company on its Stock on a dividend payment date.

(j) “Effective
Date” of the Plan means July 27, 2016, subject to approval by the stockholders of the Company.

    	 	1	 

    	 

    

 

(k) “Exchange
Act” means the Securities Exchange Act of 1934, as amended.

(l) “Fair
Market Value” of Stock is (i) if the Stock is publicly traded, then the Fair Market Value per share shall be
determined as follows: (A) if the principal trading market for the Stock is a national securities exchange, the last reported
sale price during regular trading hours on the relevant date or (if there were no trades on that date) the latest preceding date
upon which a sale was reported, or (B) if the Stock is not principally traded on such exchange or market, the mean between
the last reported “bid” and “asked” prices of Stock on the relevant date, as reported by the National Daily
Quotation Bureau, Inc. or as reported in a customary financial reporting service, as applicable and as the Administrator determines,
or (ii) if the Stock is not publicly traded or, if publicly traded, is not subject to reported transactions or “bid”
or “asked” quotations as set forth above, the Fair Market Value per share shall be as determined by the Administrator.

(m) “Grant” means
an Option, SAR, Stock Unit, Performance Share, Stock Award, Dividend Equivalent or Other Stock-Based Award granted under the Plan.

(n) “Grant
Instrument” means the written agreement that sets forth the terms and conditions of a Grant, including all amendments
thereto.

(o) “Incentive
Stock Option” means a stock option that is intended to meet the requirements of section 422 of the Code, as described
in Section 7.

(p) “Non-Employee
Director” means a non-employee director of the Company as defined by Rule 16b-3 under the Exchange Act.

(q) “Nonqualified
Stock Option” means a stock option that is not intended to meet the requirements of section 422 of the Code, as
described in Section 7.

(r) “Option” means
an Incentive Stock Option or Nonqualified Stock Option to purchase shares of Stock at an Option Price for a specified period of
time.

(s) “Option
Price” means an amount per share of Stock purchasable under an Option, as designated by the Administrator.

 

(t) “Other
Stock-Based Award” means any Grant based on, measured by or payable in Stock (other than Grants described in Sections
7, 8, 9, 10, 11 and 12), as described in Section 13.

(u) “Parent” means
a “parent corporation,” as defined in section 424(e) of the Code, of the Company.

(v) “Participant” means
an employee of the Company or an Affiliate of the Company, a member of the Board, or an individual who provides services to the
Company or an Affiliate of the Company, and is selected by the Administrator to receive a Grant under the Plan.

(w) “Performance
Shares” means an award of phantom shares, representing one or more shares of Stock, as described in Section 10.

(x) “Person” means
any individual, corporation, partnership, joint venture, limited liability company, estate, trust, or unincorporated association,
and any fiduciary acting in such capacity on behalf of any of the foregoing.

(y) “Plan” means
this CardConnect Corp. 2016 Omnibus Equity Compensation Plan, as in effect from time to time.

(z) “Qualified
Affiliate” means (i) any Person that is part of a controlled group or under common control with the Company;
(ii) any employee benefit plan (or related trust) sponsored or maintained by the Company or by any entity controlled by the
Company; or (iii) any Person controlled by any executive officer (as defined by Rule 16a-1(f) of the Exchange Act) of the
Company. For purposes of this definition, “controlled by” shall mean possessing, directly or indirectly, the power
to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities,
by contract or otherwise.

(aa) “Stock” means
the common stock, par value $0.001, of the Company or such other securities of the Company as may be substituted for Stock pursuant
to Sections 5(d) or 18.

(bb) “SAR” means
an award of a stock appreciation right, as described in Section 8.

(cc) “Stock
Award” means an award of Stock, as described in Section 11.

    	 	2	 

    	 

    

(dd) “Stock
Unit” means an award of a phantom unit, representing one or more shares of Stock, as described in Section 9.

(ee) “Subsidiary” means
any entity in which the Company has a greater than 50% ownership interest. For purposes of Sections 7(c), (d) and (h), “Subsidiary”
shall mean a “subsidiary corporation,” as defined in section 424(f) of the Code, of the Company.

(ff) “Successor
Participant” means the personal representative or other person entitled to succeed to the rights of the Participant
in accordance with Section 17.

 

	3.		Administration

(a) The
Plan shall be administered by the Administrator. The Administrator shall have the sole authority to (i) determine the Participants
to whom Grants shall be made under the Plan, (ii) determine the type, size and terms of the Grants to be made to each Participant,
(iii) determine the time when the Grants will be made and the duration of any applicable exercise or restriction period, including
the criteria for exercisability and the acceleration of exercisability, (iv) amend the terms of any previously issued Grant,
subject to the provisions of Section 20, (v) adopt guidelines separate from the Plan that set forth the specific terms
and conditions for Grants under the Plan, and (vi) deal with any other matters arising under the Plan.

(b) The
Administrator shall have full power and express discretionary authority to administer and interpret the Plan, to make factual determinations
and to adopt or amend such rules, regulations, agreements and instruments for implementing the Plan and for the conduct of its
business as it deems necessary or advisable, in its sole discretion. The Administrator’s interpretations of the Plan and
all determinations made by the Administrator pursuant to the powers vested in it hereunder shall be conclusive and binding on all
persons having any interest in the Plan or in any awards granted hereunder. All powers of the Administrator shall be executed in
its sole discretion, in the best interest of the Company, not as a fiduciary, and in keeping with the objectives of the Plan and
need not be uniform as to similarly situated individuals.

(c) The
Administrator, in its discretion, may delegate to one or more officers of the Company all or part of the Administrator’s
authority and duties with respect to grants and awards to individuals who are not subject to the reporting and other provisions
of Section 16 of the Exchange Act. The Administrator may revoke or amend the terms of a delegation at any time but such action
shall not invalidate any prior actions of the Administrator’s delegate or delegates that were consistent with the terms of
the Plan and the Administrator’s prior delegation. Any delegation by the Administrator pursuant to this Section shall be
subject to such conditions and limitations as may be determined by the Administrator and shall be subject to and limited by applicable
law or regulation, including without limitation the rules and regulations of the New York Stock Exchange or such other securities
exchange on which the Stock is then listed.

 

	4.		Grants

Grants
under the Plan may consist of Options, SARs, Stock Units, Performance Shares, Stock Awards, Dividend Equivalents and Other Stock-Based
Awards. All Grants shall be subject to the terms and conditions set forth herein and to such other terms and conditions consistent
with the Plan as the Administrator deems appropriate and as are specified in writing by the Administrator in separate guidelines
or to the individual in the Grant Instrument or an amendment to the guidelines or Grant Instrument. The Administrator shall approve
the form and provisions of each Grant Instrument. All Grants shall be made conditional upon the Participant’s acknowledgment,
in writing or by acceptance of the Grant, that all decisions and determinations of the Administrator shall be final and binding
on the Participant, his or her beneficiaries, and any other person having or claiming an interest under such Grant. Grants under
a particular Section of the Plan need not be uniform as among the Participants.

 

	5.		Shares of Stock Subject to the Plan

(a) Shares
Authorized. The total aggregate number of shares of Stock that may be issued or transferred under the Plan is 3,796,296 shares,
subject to adjustment as described below. The shares may be authorized but unissued shares of Stock or reacquired shares of Stock,
including shares purchased by the Company on the open market for purposes of the Plan. Grants paid in cash shall not count against
the foregoing share limits.

    	 	3	 

    	 

    

(b) Share
Counting. For administrative purposes, when the Administrator makes a Grant payable in Stock, the Administrator shall reserve
shares of Stock equal to the maximum number of shares of Stock that may be payable under the Grant. If and to the extent Options
or SARs granted under the Plan terminate, expire, or are canceled, forfeited, exchanged or surrendered without having been exercised
or if any Stock Awards, Stock Units, Performance Shares, Dividend Equivalents or Other Stock-Based Awards are forfeited or terminated,
or otherwise are not paid in full, the shares subject to such Grants which have not been issued shall again be available for purposes
of the Plan. Shares of Stock withheld in payment of the Option Price of an Option or withheld for purposes of satisfying the Employer’s
minimum tax withholding obligations with respect to Grants under the Plan shall not be available for re-issuance or transfer under
the Plan. Upon the exercise of an Option through the withholding of shares or upon the exercise of a SAR, then both for purposes
of calculating the number of shares of Stock remaining available for issuance under the Plan and the number of shares of Stock
remaining available for exercise under the Option or SAR, the number of such shares shall be reduced by the gross number of shares
for which the Option or SAR is exercised. To the extent that any Grants are paid in cash and not shares of Stock, such Grants shall
not count against the share limits in subsection (a) above. For the avoidance of doubt, if shares of Stock are repurchased
on the open market with the proceeds of the exercise price of Options, such shares may not again be made available for issuance
under the Plan.

(c) Individual
Limits. All Grants under the Plan, other than Dividend Equivalents, shall be expressed in shares of Stock. The maximum aggregate
number of shares of Stock with respect to which all Grants, other than Dividend Equivalents, may be made under the Plan to any
individual during any calendar year shall be 400,000 shares, subject to adjustment as described below. A Participant may not accrue
Dividend Equivalents during any calendar year in excess of $250,000. The individual limits described in this subsection (c) shall
apply without regard to whether the Grants are to be paid in Stock or in cash; provided, however, that the individual limit shall
not apply to option grants made to Jeffrey Shanahan, Patrick Shanahan and Charles Bernicker pursuant to the amended and restated
employment agreements with such individuals each dated as of July 29, 2016. All cash payments (other than Dividend Equivalents)
shall equal the Fair Market Value of the shares of Stock to which the cash payment relates.

(d) Adjustments.
If there is any change in the number or kind of shares of Stock outstanding (i) by reason of a stock dividend, spinoff, recapitalization,
stock split, or combination or exchange of shares, (ii) by reason of a merger, reorganization or consolidation, (iii) by
reason of a reclassification or change in par value, or (iv) by reason of any other extraordinary or unusual event affecting
the outstanding Stock as a class without the Company’s receipt of consideration, or if the value of outstanding shares of
Stock is substantially reduced as a result of a spinoff or the Company’s payment of an extraordinary dividend or distribution,
the maximum number of shares of Stock available for issuance under the Plan, the maximum number of shares of Stock for which any
individual may receive pursuant to Grants in any year, the number of shares covered by outstanding Grants, the kind of shares to
be issued or transferred under the Plan, and the price per share or the applicable market value of such Grants shall be equitably
adjusted by the Administrator, in such manner as the Administrator deems appropriate, to reflect any increase or decrease in the
number of, or change in the kind or value of, issued shares of Stock to preclude, to the extent practicable, the enlargement or
dilution of rights and benefits under such Grants; provided, however, that any fractional shares resulting from such adjustment
shall be eliminated. In addition, in the event of a Change of Control of the Company, the provisions of Section 18 of the
Plan shall apply. Any adjustments to outstanding Grants shall be consistent with section 409A or 424 of the Code, to the extent
applicable. Any adjustments determined by the Administrator shall be final, binding and conclusive.

 

	6.		Eligibility for Participation

Any
employee of the Company or an Affiliate of the Company, any member of the Board and any individual who provides services to the
Company or an Affiliate of the Company is eligible to participate in this Plan if the Administrator, in its sole discretion, determines
that such person has contributed significantly or can be expected to contribute significantly to the profits or growth of the Company
or an Affiliate of the Company. Grants will be made only to persons who are employees, directors, consultants or advisors of the
Company for purposes of Form S-8 registration under the Securities Act of 1933, as amended. Options and SARs may be granted only
to persons who perform direct services to the Company on the date of grant, as determined under section 409A of the Code.

    	 	4	 

    	 

    

	7.		Options

(a) General
Requirements. The Administrator may grant Options to a Participant upon such terms and conditions as the Administrator deems
appropriate under this Section 7.

(b) Number
of Shares. The Administrator shall determine the number of shares of Stock that will be subject to each Grant of Options to
Participants.

(c) Type
of Option and Price.

(i)
The Administrator may grant Incentive Stock Options or Nonqualified Stock Options or any combination of Incentive Stock Options
and Nonqualified Stock Options. Incentive Stock Options may be granted only to employees of the Company or its Subsidiaries. No
Option that is intended to be an Incentive Stock Option shall be invalid for failure to qualify as an Incentive Stock Option. Nonqualified
Stock Options may be granted to any Participant.

(ii)
The Option Price shall be determined by the Administrator and may be equal to or greater than the Fair Market Value of the shares
of Stock subject to the Grant on the Date of Grant; provided, however, that an Incentive Stock Option may not be granted to any
person who, at the Date of Grant, owns stock possessing more than 10 percent of the total combined voting power of all classes
of stock of the Company or any Subsidiary, unless the Option Price is not less than 110% of the Fair Market Value on the Date of
Grant.

(d) Option
Term. The Administrator shall determine the term of each Option. The term of an Option shall not exceed ten years from the
Date of Grant. However, an Incentive Stock Option that is granted to an Employee who, at the Date of Grant, owns stock possessing
more than 10 percent of the total combined voting power of all classes of stock of the Company, or any Subsidiary, may not have
a term that exceeds five years from the Date of Grant.

(e) Exercisability
of Options. Options shall become exercisable in accordance with such terms and conditions as may be determined by the
Administrator and specified in the Grant Instrument. The Administrator may accelerate the exercisability of any or all outstanding
Options at any time for any reason.

(f) Termination
of Employment or Service. Except as provided in the Grant Instrument, an Option may only be exercised while the Participant
is employed by, or providing service to, the Company, an Affiliate or another entity as designated in the Grant Instrument. The
Administrator shall specify in the Grant Instrument under what circumstances and during what time periods a Participant may exercise
an Option after termination of employment or service.

(g) Exercise
of Options. A Participant may exercise an Option that has become exercisable, in whole or in part, by delivering a notice of
exercise to the Company or its designated agent. The Participant shall pay the Option Price and any withholding taxes for the Option
(i) in cash or by certified check, (ii) with the approval of the Administrator, by withholding shares of Stock subject
to the Option, by delivering shares of Stock owned by the Participant or by attestation (on a form prescribed by the Administrator)
to ownership of shares of Stock (in each case, such shares of Stock shall have an aggregate Fair Market Value on the date of exercise
equal to the Option Price), (iii) in cash, on the T+3 settlement date that occurs after the exercise date specified in the
notice of exercise, provided that the Participant exercises the Option through an irrevocable agreement with a registered broker
and the payment is made in accordance with procedures permitted by Regulation T of the Federal Reserve Board and such procedures
do not violate applicable law, or (iv) by such other method as the Administrator may approve, to the extent permitted by applicable
law. Shares of Stock used to exercise an Option shall have been held by the Participant for the requisite period of time to avoid
adverse accounting consequences to the Company with respect to the Option. Payment for the shares pursuant to the Option, and any
required withholding taxes, must be received by the time specified by the Administrator depending on the type of payment being
made.

 

(h) Limits
on Incentive Stock Options. Each Incentive Stock Option shall provide that if the aggregate Fair Market Value on the Date of
Grant with respect to which Incentive Stock Options are exercisable for the first time by a Participant during any calendar year,
under the Plan or any other stock option plan of the Company or a Parent or Subsidiary, exceeds $100,000, then the Option, as to
the excess, shall be treated as a Nonqualified Stock Option.

 

	8.		SARs

(a) General
Requirements. The Administrator may grant SARs to any Participant, upon such terms and conditions as the Administrator deems
appropriate under this Section 8. Each SAR shall represent the right of the Participant to receive, upon settlement of the
SAR, shares of Stock or cash equal to the amount by which the Fair Market Value of a share of Stock on the date of exercise of
the SAR exceeds the base amount of the SAR as described below in Section 8(c).

 

    	 	5	 

    	 

    

 

(b) Terms
of SARs. The Administrator shall determine the terms and conditions of SARs and may grant SARs separately from or in tandem
with any Option (for all or a portion of the applicable Option). Tandem SARs may be granted either at the time the Option is granted
or any time thereafter while the Option remains outstanding; provided, however, that in the case of an Incentive Stock Option,
SARs may be granted only at the time of the grant of the Incentive Stock Option. The Administrator will determine the number of
SARs to be granted, the base amount, the vesting and other restrictions applicable to SARs and the period during which SARs will
remain exercisable. The term of SARs shall not exceed ten years from the Date of Grant.

(c) Base
Amount. The Administrator shall establish the base amount of the SAR at the time the SAR is granted. The base amount shall
not be less than the Fair Market Value of the shares of Stock subject to the Grant on the Date of Grant.

(d) Payment
With Respect to SARs. The Administrator shall determine whether the appreciation in an SAR shall be paid in the form of cash,
in Stock, or in a combination of the two, in such proportion as the Administrator deems appropriate. For purposes of calculating
the number of shares of Stock to be received, Stock shall be valued at its Fair Market Value on the date of exercise of the SAR.
If shares of Stock are to be received upon exercise of an SAR, cash shall be delivered in lieu of any fractional share.

(e) Requirement
of Employment or Service. The Administrator shall determine in the Grant Instrument under what circumstances a Participant
may retain SARs after termination of the Participant’s employment or service, and the circumstances under which SARs may
be forfeited.

 

	9.		Stock Units

(a) General
Requirements. The Administrator may grant Stock Units to a Participant, upon such terms and conditions as the Administrator
deems appropriate under this Section 9. Each Stock Unit shall represent the right of the Participant to receive a share of
Stock or an amount based on the value of a share of Stock. All Stock Units shall be credited to accounts on the Company’s
records for purposes of the Plan.

(b) Terms
of Stock Units. The Administrator may grant Stock Units that are payable if specified performance goals or other conditions
are met, or under other circumstances. Stock Units may be paid at the end of a specified period, or payment may be deferred to
a date authorized by the Administrator. The Administrator shall determine the number of Stock Units to be granted and the requirements
applicable to such Stock Units.

 

(c) Payment
With Respect to Stock Units. Payment with respect to Stock Units shall be made in cash, in Stock, or in a combination of the
two, as determined by the Administrator. The Grant Instrument shall specify the maximum number of shares that shall be paid under
the Stock Units.

(d) Requirement
of Employment or Service. The Administrator shall determine in the Grant Instrument under what circumstances a Participant
may retain Stock Units after termination of the Participant’s employment or service, and the circumstances under which Stock
Units may be forfeited.

 

	10.		Performance Shares

(a) General
Requirements. The Administrator may grant Performance Shares to a Participant, upon such terms and conditions as the Administrator
deems appropriate under this Section 10. Each Performance Share shall represent the right of the Participant to receive a
share of Stock or an amount based on the value of a share of Stock, if specified performance goals are met. All Performance Shares
shall be credited to accounts on the Company’s records for purposes of the Plan.

(b) Terms
of Performance Shares. The Administrator shall establish the performance goals and other conditions for payment of Performance
Shares. Performance Shares may be paid at the end of a specified performance or other period, or payment may be deferred to a date
authorized by the Administrator. The Administrator shall determine the number of Performance Shares to be granted and the requirements
applicable to such Performance Shares.

(c) Payment
With Respect to Performance Shares. Payment with respect to Performance Shares shall be made in cash, in Stock, or in a combination
of the two, as determined by the Administrator. The Administrator may establish in the Grant Instrument a target amount to be paid
under a Performance Share based on achievement of the performance goals.

    	 	6	 

    	 

    

(d) Requirement
of Employment or Service. The Administrator shall determine in the Grant Instrument under what circumstances a Participant
may retain Performance Shares after termination of the Participant’s employment or service, and the circumstances under which
Performance Shares may be forfeited.

 

	11.		Stock Awards

(a) General
Requirements. The Administrator may issue or transfer shares of Stock to a Participant under a Stock Award, upon such terms
and conditions as the Administrator deems appropriate under this Section 11. Shares of Stock issued or transferred pursuant
to Stock Awards may be issued or transferred for cash consideration or for no cash consideration, and subject to restrictions or
no restrictions, as determined by the Administrator. The Administrator may establish conditions under which restrictions on Stock
Awards shall lapse over a period of time or according to such other criteria as the Administrator deems appropriate, including
restrictions based upon the achievement of specific performance goals.

(b) Number
of Shares. The Administrator shall determine the number of shares of Stock to be issued or transferred pursuant to a Stock
Award and any restrictions applicable to such shares.

(c) Requirement
of Employment or Service. The Administrator shall determine in the Grant Instrument under what circumstances a Participant
may retain Stock Awards after termination of the Participant’s employment or service, and the circumstances under which Stock
Awards may be forfeited.

 

(d) Restrictions
on Transfer. While Stock Awards are subject to restrictions, a Participant may not sell, assign, transfer, pledge or otherwise
dispose of the shares of a Stock Award except upon death as described in Section 17. Each certificate, or electronic book
entry equivalent, for a share of a Stock Award shall contain a legend giving appropriate notice of the restrictions in the Grant.
The Participant shall be entitled to have the legend removed when all restrictions on such shares have lapsed. The Administrator
may retain possession of any stock certificates for Stock Awards until all restrictions on such shares have lapsed.

(e) Right
to Vote and to Receive Dividends. The Administrator shall determine to what extent, and under what conditions, the Participant
shall have the right to vote shares of Stock Awards and to receive any dividends or other distributions paid on such shares during
the restriction period. The Administrator may determine that a Participant’s entitlement to dividends or other distributions
with respect to a Stock Award shall be subject to achievement of performance goals or other conditions.

 

	12.		Dividend Equivalents

(a) General
Requirements. When the Administrator makes a Grant under the Plan, other than an Option or SAR, the Administrator may grant
Dividend Equivalents in connection with such Grants, under such terms and conditions as the Administrator deems appropriate under
this Section 12. Dividend Equivalents may be paid to Participants currently or may be deferred, as determined by the Administrator.
All Dividend Equivalents that are not paid currently shall be credited to accounts on the Company’s records for purposes
of the Plan. Dividend Equivalents may be accrued as a cash obligation, or may be converted to Stock Units for the Participant,
as determined by the Administrator. Unless otherwise specified in the Grant Instrument, deferred Dividend Equivalents will not
accrue interest. The Administrator may provide that Dividend Equivalents shall be payable based on the achievement of specific
performance goals. Dividend Equivalents may accrue on unearned performance awards but shall not be payable unless and until such
performance metrics are met.

(b) Payment
with Respect to Dividend Equivalents. Dividend Equivalents may be payable in cash or shares of Stock or in a combination of
the two, as determined by the Administrator.

    	 	7	 

    	 

    

	13.		Other Stock-Based Awards

The Administrator
may grant other awards that are cash-based or based on, measured by or payable in Stock to Participants, on such terms and conditions
as the Administrator deems appropriate under this Section 13. Other Stock-Based Awards may be granted subject to
achievement of performance goals or other conditions and may be payable in Stock or cash, or in a combination of the two, as determined
by the Administrator in the Grant Instrument.

 

	14.		Qualified Performance-Based Compensation

(a) Designation
as Qualified Performance-Based Compensation. The Administrator may determine that Stock Units, Performance Shares, Stock Awards,
Dividend Equivalents or Other Stock-Based Awards granted to an Employee shall be considered “qualified performance-based
compensation” under section 162(m) of the Code. The provisions of this Section 14 shall apply to any such Grants that
are to be considered “qualified performance-based compensation” under section 162(m) of the Code. To the extent that
Grants of Stock Units, Performance Shares, Stock Awards, Dividend Equivalents or Other Stock-Based Awards designated as “qualified
performance-based compensation” under section 162(m) of the Code are made, no such Grant may be made as an alternative to
another Grant that is not designated as “qualified performance based compensation” but instead must be separate and
apart from all other Grants made.

 

(b) Performance
Goals. When Stock Units, Performance Shares, Stock Awards, Dividend Equivalents or Other Stock-Based Awards that are to be
considered “qualified performance-based compensation” are granted, the Administrator shall establish in writing (i) the
objective performance goals that must be met, (ii) the period during which performance will be measured, (iii) the maximum
amounts that may be paid if the performance goals are met, and (iv) any other conditions that the Administrator deems appropriate
and consistent with the Plan and the requirements of section 162(m) of the Code for “qualified performance-based compensation.”
The performance goals shall satisfy the requirements for “qualified performance-based compensation,” including the
requirement that the achievement of the goals be substantially uncertain at the time they are established and that the performance
goals be established in such a way that a third party with knowledge of the relevant facts could determine whether and to what
extent the performance goals have been met. The Administrator shall not have discretion to increase the amount of compensation
that is payable upon achievement of the designated performance goals, but the Administrator may reduce the amount of compensation
that is payable upon achievement of the designated performance goals.

(c) Criteria
Used for Objective Performance Goals. The Administrator shall use objectively determinable performance goals based on one or
more of the following criteria: Stock price, earnings per share of Stock, net earnings, operating earnings, return on assets, stockholder
return, return on equity, growth in assets, unit volume, sales, market share, or strategic business criteria consisting of one
or more objectives based on meeting specific revenue goals, market penetration goals, geographic business expansion goals, cost
targets or goals relating to acquisitions or divestitures. The performance goals may relate to the Participant’s business
unit or the performance of the Company, a Subsidiary, or the Company and its Subsidiaries as a whole, or any combination of the
foregoing. Performance goals need not be uniform as among Participants.

(d) Timing
of Establishment of Goals. The Administrator shall establish the performance goals in writing either before the beginning of
the performance period or during a period ending no later than the earlier of (i) 90 days after the beginning of the performance
period or (ii) the date on which 25% of the performance period has been completed, or such other date as may be required or
permitted under applicable regulations under section 162(m) of the Code.

(e) Certification
of Results. The Administrator shall certify and announce the results for the performance period to all Participants after the
Company announces the Company’s financial results for the performance period. The Administrator shall determine the amount,
if any, to be paid pursuant to each Grant based on the achievement of the performance goals and the terms of each Grant Instrument.

(f) Death,
Disability or Other Circumstances. The Administrator may provide in the Grant Instrument that Grants shall be payable, in whole
or in part, in the event of the Participant’s death or disability, a Change of Control or under other circumstances consistent
with the Treasury regulations and rulings under section 162(m) of the Code.

    	 	8	 

    	 

    

 

	15.		Deferrals

The Administrator
may permit or require a Participant to defer receipt of the payment of cash or the delivery of shares of Stock that would otherwise
be due to the Participant in connection with any Grant. The Administrator shall establish rules and procedures for such deferrals.
Any deferrals under the Plan shall be intended to comply with the requirements of section 409A of the Code, and any corresponding
regulations and guidance.

 

	16.		Withholding of Taxes

(a) Required
Withholding. All Grants under the Plan shall be subject to applicable federal (including FICA), state and local tax withholding
requirements. The Employer may require that the Participant or other person receiving or exercising Grants pay to the Employer
the amount of any federal, state or local taxes that the Employer is required to withhold with respect to such Grants, or the Employer
may deduct from other wages paid by the Employer the amount of any withholding taxes due with respect to such Grants.

(b) Election
to Withhold Shares. If the Administrator so permits, a Participant may elect to satisfy the Employer’s tax withholding
obligation with respect to Grants paid in Stock by having shares withheld, at the time such Grants become taxable, up to an amount
that does not exceed the minimum applicable withholding tax rate for federal (including FICA), state and local tax liabilities.
In addition, with respect to any required tax withholding amount that exceeds the minimum applicable withholding tax rate, the
Administrator may permit a Participant to satisfy such tax withholding obligation with respect to such excess amount by providing
that the Participant may elect to deliver to the Company shares of Stock owned by the Participant that have been held by the Participant
for the requisite period of time to avoid adverse accounting consequences to the Company. The elections described in this subsection
(b) must be in a form and manner prescribed by the Administrator and may be subject to the prior approval of the Administrator.

 

	17.		Transferability of Grants

(a) In
General. Except as provided in this Section 17, only the Participant may exercise rights under a Grant during the Participant’s
lifetime. A Participant may not transfer those rights except by will or by the laws of descent and distribution, or, with respect
to Grants other than Incentive Stock Options, if permitted in any specific case by the Administrator, pursuant to a domestic relations
order. When a Participant dies, the Successor Participant may exercise such rights in accordance with the terms of the Plan. A
Successor Participant must furnish proof satisfactory to the Company of his or her right to receive the Grant under the Participant’s
will or under the applicable laws of descent and distribution.

(b) Transfer
of Nonqualified Stock Options. Notwithstanding the foregoing, the Administrator may provide in a Grant Instrument that a Participant
may transfer Nonqualified Stock Options to family members of the Participant, one or more trusts in which family members of the
Participant have more than 50% of the beneficial interest, foundations in which family members of the Participant (or the Participant)
control the management of assets, or any other entity in which family members of the Participant (or the Participant) own more
than 50% of the voting interests, consistent with applicable securities laws, according to such terms as the Administrator may
determine; provided that the Participant receives no consideration for the transfer of a Nonqualified Stock Option and the transferred
Nonqualified Stock Option shall continue to be subject to the same terms and conditions as were applicable to the Nonqualified
Stock Option immediately before the transfer.

 

	18.		Consequences of a Change of Control

(a) Assumption
of Grants. Upon a Change of Control where the Company is not the surviving corporation (or survives only as a subsidiary of
another corporation), unless the Administrator determines otherwise, all outstanding Options and SARs that are not exercised shall
be assumed by, or replaced with comparable options or rights by, the surviving corporation (or a parent or subsidiary of the surviving
corporation), and other outstanding Grants shall be converted to similar grants of the surviving corporation (or a parent or subsidiary
of the surviving corporation).

(b) Other
Alternatives. Notwithstanding the foregoing, in the event of a Change of Control, the Administrator may take any of the following
actions with respect to any or all outstanding Grants: the Administrator may (i) determine that outstanding Options and SARs
shall accelerate and become exercisable, in whole or in part, upon the Change of Control or upon such other event as the Administrator
determines, (ii) determine that the restrictions and conditions on outstanding Stock Awards shall lapse, in whole or in part,
upon the Change of Control or upon such other event as the Administrator determines, (iii) determine that Participants holding
Stock Units, Performance Shares, Dividend Equivalents, and Other Stock-Based Awards shall receive a payment in settlement of such
Stock Units, Performance Shares, Dividend Equivalents, and Other Stock-Based Awards in an amount determined by the Administrator,
(iv) require that Participants surrender their outstanding Options and SARs in exchange for a payment by the Company, in cash
or Stock, as determined by the Administrator, in an amount equal to the amount by which the then Fair Market Value of the shares
of Stock subject to the Participant’s unexercised Options and SARs exceeds the Option Price of the Options or the base amount
of SARs, as applicable, or (v) after giving Participants an opportunity to exercise their outstanding Options and SARs, terminate
any or all unexercised Options and SARs at such time as the Administrator deems appropriate. Such surrender, termination or settlement
shall take place as of the date of the Change of Control or such other date as the Administrator may specify. The Administrator
shall have no obligation to take any of the foregoing actions, and, in the absence of any such actions, outstanding Grants shall
continue in effect according to their terms (subject to any assumption pursuant to subsection (a)).

    	 	9	 

    	 

    

(c) Administrator.
The Administrator making the determinations under this Section 18 following a Change of Control must be comprised of the same
members as those constituting the Administrator immediately before the Change of Control.

 

	19.		Requirements for Issuance of Shares

 

No shares
of Stock shall be issued or transferred in connection with any Grant hereunder unless and until all legal requirements applicable
to the issuance of such Stock have been complied with to the satisfaction of the Administrator. The Administrator shall have the
right to condition any Grant made to any Participant hereunder on such Participant’s undertaking in writing to comply with
such restrictions on his or her subsequent disposition of such shares of Stock as the Administrator shall deem necessary or advisable,
and certificates representing such shares may be legended to reflect any such restrictions. Certificates representing shares of
Stock issued or transferred under the Plan will be subject to such stop-transfer orders and other restrictions as may be required
by applicable laws, regulations and interpretations, including any requirement that a legend be placed thereon.

 

	20.		Amendment and Termination of the Plan

(a) Amendment.
The Board may amend or terminate the Plan at any time; provided, however, that the Board shall not amend the Plan without approval
of the stockholders of the Company if such approval is required in order to comply with the Code, applicable laws and stock exchange
requirements, or as required by Section 21(b) below. No amendment or termination of this Plan shall, without the consent of
the Participant, impair any rights or obligations under any Grant previously made to the Participant, unless such right has been
reserved in the Plan or the Grant Instrument, or except as provided in Section 21(b) below.

(b) No
Repricing Without Stockholder Approval. Except in connection with a corporate transaction involving the Company (including,
without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation,
split-up, spin-off, combination, or exchange of shares), the terms of outstanding awards may not be amended to reduce the exercise
price of outstanding Options or SARs or cancel outstanding Options or SARs in exchange for cash, other awards or Options or SARs
with an exercise price that is less than the exercise price of the original Options or SARs without stockholder approval.

(c) Stockholder
Approval for “Qualified Performance-Based Compensation.” If Stock Units, Performance Shares, Stock Awards, Dividend
Equivalents or Other Stock-Based Awards are granted as “qualified performance-based compensation” under Section 14
above, the Plan must be reapproved by the Company’s stockholders no later than the first stockholders meeting that occurs
in the fifth year following the year in which the stockholders previously approved the provisions of Section 14, if additional
Grants are to be made under Section 14 and if required by section 162(m) of the Code or the regulations thereunder.

 

(d) Termination
of Plan. The Plan shall terminate on the day immediately preceding the tenth anniversary of its Effective Date, which is July
27, 2026, unless the Plan is terminated earlier by the Board or is extended by the Board with the approval of the stockholders.
The termination of the Plan shall not impair the power and authority of the Administrator with respect to an outstanding Grant.

    	 	10	 

    	 

    

 

	21.		Miscellaneous

(a) Grants
in Connection with Corporate Transactions and Otherwise. Nothing contained in this Plan shall be construed to (i) limit
the right of the Administrator to make Grants under this Plan in connection with the acquisition, by purchase, lease, merger, consolidation
or otherwise, of the business or assets of any corporation, firm or association, including Grants to employees thereof who become
Employees, or for other proper corporate purposes, or (ii) limit the right of the Company to grant stock options or make other
awards outside of this Plan. Without limiting the foregoing, the Administrator may make a Grant to an employee of another corporation
who becomes an Employee by reason of a corporate merger, consolidation, acquisition of stock or property, reorganization or liquidation
involving the Company in substitution for a grant made by such corporation. The terms and conditions of the substitute Grants may
vary from the terms and conditions required by the Plan and from those of the substituted stock incentives. The Administrator shall
prescribe the provisions of the substitute Grants.

(b) Compliance
with Law.

(i)
The Plan, the exercise of Options or SARs and the obligations of the Company to issue or transfer shares of Stock under Grants
shall be subject to all applicable laws and to approvals by any governmental or regulatory agency as may be required. With respect
to persons subject to section 16 of the Exchange Act, it is the intent of the Company that the Plan and all transactions under
the Plan comply with all applicable provisions of Rule 16b-3 or its successors under the Exchange Act. In addition, it is the intent
of the Company that the Plan and applicable Grants comply with the applicable provisions of sections 162(m), 409A and 422 of the
Code. To the extent that any legal requirement of section 16 of the Exchange Act or sections 162(m), 409A or 422 of the Code as
set forth in the Plan ceases to be required under section 16 of the Exchange Act or sections 162(m), 409A or 422 of the Code, that
Plan provision shall cease to apply. The Administrator may revoke any Grant if it is contrary to law or modify a Grant to bring
it into compliance with any valid and mandatory government regulation. The Administrator may also adopt rules regarding the withholding
of taxes on payments to Participants. The Administrator may, in its sole discretion, agree to limit its authority under this Section.

(ii)
The Plan is intended to comply with the requirements of section 409A of the Code, to the extent applicable. Each Grant shall be
construed and administered such that the Grant either (A) qualifies for an exemption from the requirements of section 409A
of the Code or (B) satisfies the requirements of section 409A of the Code. If a Grant is subject to section 409A of the Code,
(I) distributions shall only be made in a manner and upon an event permitted under section 409A of the Code, (II) payments
to be made upon a termination of employment shall only be made upon a “separation from service” under section 409A
of the Code, (III) unless the Grant specifies otherwise, each installment payment shall be treated as a separate payment for purposes
of section 409A of the Code, and (IV) in no event shall a Participant, directly or indirectly, designate the calendar year in which
a distribution is made except in accordance with section 409A of the Code.

(iii)
Any Grant that is subject to section 409A of the Code and that is to be distributed to a Key Employee (as defined below) upon separation
from service shall be administered so that any distribution with respect to such Grant shall be postponed for six months following
the date of the Participant’s separation from service, if required by section 409A of the Code. If a distribution is delayed
pursuant to section 409A of the Code, the distribution shall be paid within 15 days after the end of the six-month period. If the
Participant dies during such six-month period, any postponed amounts shall be paid within 90 days of the Participant’s death.
The determination of Key Employees, including the number and identity of persons considered Key Employees and the identification
date, shall be made by the Administrator or its delegate in accordance with section 416(i) of the Code and the “specified
employee” requirements of section 409A of the Code.

(c) Enforceability.
The Plan shall be binding upon and enforceable against the Company and its successors and assigns.

(d) Funding
of the Plan; Limitation on Rights. This Plan shall be unfunded. Neither the Company nor any other Employer shall be required
to establish any special or separate fund or to make any other segregation of assets to assure the payment of any Grants under
this Plan. Nothing contained in the Plan and no action taken pursuant hereto shall create or be construed to create a fiduciary
relationship between the Company or any other Employer and any Participant or any other person. No Participant or any other person
shall under any circumstances acquire any property interest in any specific assets of the Company or any other Employer. To the
extent that any person acquires a right to receive payment from the Company hereunder, such right shall be no greater than the
right of any unsecured general creditor of the Company.

    	 	11	 

    	 

    

 

(e) Rights
of Participants. Nothing in this Plan shall entitle any Participant or other person to any claim or right to receive a Grant
under this Plan. Neither this Plan nor any action taken hereunder shall be construed as giving any individual any rights to be
retained by or in the employment or service of the Employer.

(f) No
Fractional Shares. No fractional shares of Stock shall be issued or delivered pursuant to the Plan or any Grant. The Administrator
shall determine whether cash, other awards or other property shall be issued or paid in lieu of such fractional shares or whether
such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.

(g) Clawback
Policies. All Grants under the Plan are subject to the applicable provisions of the Company’s clawback or recoupment
policy approved by the Board, if any, as such policy may be in effect from time to time.

(h) Governing
Law. The validity, construction, interpretation and effect of the Plan and Grant Instruments issued under the Plan shall be
governed and construed by and determined in accordance with the laws of the State of Delaware, without giving effect to the conflict
of laws provisions thereof.

 

 

    	 	12Exhibit 10.1

 

Confidential portions of this document have been redacted and
omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the “SEC”)
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with
the notation “*” and have been filed separately with the SEC.

 

DEFINITIVE

 

LICENSE AND TRANSFER
AGREEMENT

 

This Definitive License and Transfer Agreement
(the “Agreement”) is entered into with effect as of June 6, 2016 (the “Effective Date”) by and between
Pieris Pharmaceuticals, Inc., a Nevada corporation with a place of business at 255 State Street, 9th Floor, Boston,
MA 02109 and Pieris Pharmaceuticals GmbH, a German company with a place of business at Lise-Meitner-Strasse 30, 85354 Freising,
Germany (collectively and together with their Affiliates, “Pieris”) and Enumeral Biomedical Holdings, Inc.,
a Delaware corporation with a place of business at 200 CambridgePark Drive, Suite 2000, Cambridge, MA 02140 (together with its
Affiliates, “Enumeral”).

 

Whereas, Enumeral possesses proprietary
technology and intellectual property rights related to certain antibodies; and

 

Whereas, Pieris wishes to obtain one or
more of such antibodies for development and commercialization and a license to intellectual property related to such antibodies;
and

 

Whereas, Enumeral is willing to provide
such antibodies and license such intellectual property to Pieris for development and commercialization of novel compounds comprising
fusion proteins based on such antibodies in oncology;

 

Whereas, the Parties previously entered
into a license and transfer agreement effective April 18, 2016 (the “Original Agreement”) that contemplated
the execution of this Definitive License and Transfer Agreement to fully set forth the terms of Enumeral’s license and transfer
to Pieris; and

 

Therefore, in consideration of the mutual
covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows:

 

1. Definitions. As used in this Agreement, the following
terms, whether used in the singular or plural, shall have the following meanings:

 

Affiliate. The term “Affiliate”
shall mean any individual, corporation, association or other business entity that directly or indirectly controls, is controlled
by, or is under common control with the Party in question. As used in this definition of “Affiliate” only, the term
“control” shall mean the direct or indirect ownership of more than fifty percent (>50%) of the stock having the
right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity
whether through the ownership of voting securities, by contract, resolution, regulation or otherwise.

 

    Page 1 of 25

     

    

 

Anticalin®. The term “Anticalin”
shall mean any mutein of any lipocalin protein or nucleic acid encoding such protein. The term “mutein” shall mean
a protein or nucleic acid obtained as a result of a mutation or a recombinant DNA procedure.

 

BLA. The term “BLA” or “Biologics
License Application” shall mean a request to the FDA for permission to introduce, or deliver for introduction, a biologic
product into interstate commerce under 21 CFR § 601.2 or its foreign equivalent.

 

Calendar Quarter. The term “Calendar
Quarter” means each three-month period in any year commencing with January 1 of such year.

 

Commercially Reasonable Efforts. The term
“Commercially Reasonable Efforts” shall mean such level of efforts required to carry out such obligation in a manner
consistent with the efforts that a pharmaceutical company comparable with Pieris would devote at the same stage of development
or commercialization, as applicable, for its own internally developed therapeutic products in a similar area with similar market
potential, at a similar stage of its product life, taking into account the existence of other competitive products in the market
place or under development, the proprietary position of the product, the regulatory structure involved, intellectual property considerations,
the anticipated profitability of the product and other relevant factors. It is understood that such product potential may change
from time to time based upon changing scientific, business and marketing and return on investment considerations. For avoidance
of any doubt, the fact that there may be competing product developments within Pieris shall not constitute a factor to be taken
into account in the determination of Commercially Reasonable Efforts. Further, for the avoidance of doubt, Commercially Reasonably
Efforts do not require Pieris to seek to market any therapeutic product in every country or seek to obtain regulatory approval
in every country or for every potential Indication.

 

Confidential Information. The term “Confidential
Information” means all nonpublic information disclosed in oral, written, electronic or other form or otherwise learned by
the Party receiving such information (the “Recipient”), including but not limited to information regarding the
activities of the party disclosing such information (the “Discloser”), such as research, development, preclinical
and clinical programs, data and results; pharmaceutical or biologic candidates and products; inventions, works of authorship, trade
secrets, processes, conceptions, formulas, patents, patent applications, and licenses; business, product, marketing, sales, scientific
and technical strategies, programs and results, including costs and prices; suppliers, manufacturers, customers, market data, personnel,
and consultants; and other confidential matters related to Discloser. Pieris’ Confidential Information shall specifically
include any and all non-public sequence information provided by Pieris to Enumeral of Anticalin proteins and/or lipocalin muteins,
any and all therapeutic or diagnostic information of Anticalin proteins and/or lipocalin muteins including any therapeutic drug
programs derived therefrom, any and all information disclosed by Pieris to Enumeral relating to target molecules of Anticalin proteins;
provided however that Pieris shall not disclose any information related to the target molecules of any Anticalin to Enumeral without
the prior written consent of Enumeral. “Enumeral Confidential Information” shall be Confidential Information disclosed
by Enumeral and “Pieris Confidential Information” shall be Confidential Information disclosed by Pieris.

 

    Page 2 of 25

     

    

 

Developed IP. The term “Developed
IP” shall have the meaning set forth in Section 6.

 

Enumeral IP. The term “Enumeral IP”
shall mean (i) Know-How Enumeral owns or controls with respect to the First Antibody as of the Effective Date, (ii) Know-How Enumeral
owns or controls with respect to any Subsequent Antibod(ies) as of the Option Exercise Date (as defined in Section 4.7) and (iii)
the Patent Rights Enumeral owns or controls during the Term that are necessary for Pieris to develop and commercialize Products
under this Agreement, including but not limited to the Patent Rights that cover the First Antibody and, as of an Option Exercise
Date, any Subsequent Antibod(ies) for which the Subsequent Antibody Option was exercised; and in the case of each clause (i), (ii)
and (iii) only as such Know How and Patent Rights relate to the First Antibody and/or any Subsequent Antibod(ies), methods of using,
administering, manufacturing or formulating said First Antibody or Subsequent Antibod(ies). Such Patent Rights owned by Enumeral
as of the Effective Date are listed in Exhibit A.

 

Exclusive Field. The term “Exclusive
Field” shall mean any use or activity within the Field that involves a First Antibody or a Subsequent Antibody fused with
or linked to one or more Anticalin proteins.

 

Field. The term “Field” shall
mean, all therapeutic, prophylactic, diagnostic and palliative uses in oncology.

 

First Antibody. The term “First Antibody”
shall mean, individually and collectively, the anti-PD-1 antibody clones listed in Exhibit B, and all Modifications thereof.
To the extent that any Patent Rights in the Enumeral IP include any claim(s) that relate to any antibody other than those listed
in Exhibit B, the First Antibody shall be limited the particular antibody clones listed in Exhibits B, and any Modifications
thereof.

 

FDA. The term “FDA” shall mean
the U.S. Food and Drug Administration.

 

GLP Tox Study. The term “GLP
Tox Study” means, with respect to a Product, a study conducted in accordance with GLP for the purposes of assessing the efficacy,
safety or the onset, severity, and duration of toxic effects and their dose dependency to establish a profile sufficient to support
the filing of an investigational new drug application.

 

Good Laboratory Practice or GLP.  The
term “Good Laboratory Practice” or “GLP” means the then-current Good Laboratory Practice Standards
promulgated or endorsed by FDA or in the case of any other country in the Territory, comparable regulatory standards promulgated
or endorsed by that country, including those procedures expressed in or contemplated by any regulatory filings.

 

Indication. The term “Indication”
shall mean a distinct type of disease or medical condition in humans to which a Product is directed and eventually approved in
the Field. To distinguish one Indication from another Indication, the two Indications have to be (i) listed in two different blocks
of the Tenth Revision of the International Classifications of Diseases and Related Health Problems of 2010 (as a way of example,
any neoplasm under C15 is in a different block from any neoplasm under block C16, whereas C15.0 and C15.1 belong to the same block),
and (ii) developed under a separate Phase II Clinical Trial and Phase III Clinical Trial.

 

    Page 3 of 25

     

    

 

Know-How. The term “Know-How”
shall mean sequence information, data, knowledge and information, including chemical manufacturing data, toxicological data, pharmacological
data, preclinical data, formulations, specifications, quality control testing data, that are necessary or useful for the discovery,
manufacture, development or commercialization of any Product existing as of the date of this Agreement with respect to the First
Antibody, and as of the Option Exercise Date with respect to any Subsequent Antibody. For purposes of this Agreement, Know-How
does not include antibody screening technology. Notwithstanding anything in this definition of Know-How, Enumeral shall be under
no obligation to provide samples of the First Antibody or any Subsequent Antibody.

 

Maintenance Fee. The
term “Maintenance Fee” shall have the meaning set forth in Section 4.

 

Major Markets. The term
Major Markets means the territories of North America, European Union and Japan.

 

Marketing Authorization.
The term “Marketing Authorization” shall mean shall mean any approvals, licenses, registrations or authorizations,
including any pricing approvals, necessary for the sale of a Product on the market in any country of the Territory as granted by
a competent regulatory authority.

 

Modifications. The term
“Modifications” means an alteration, mutation or derivative of the First Antibody or any Subsequent Antibody invented,
conceived or reduced to practice by or on behalf of Pieris, its Affiliates or its Sublicensees. For avoidance of doubt, Modification
shall not mean the First Antibody or any Subsequent Antibody fused with or linked to an Anticalin.

 

Net Sales. The term “Net
Sales” shall mean for a Product in a particular period, the sum of (1) and (2):

 

(1) the gross amount invoiced
by Pieris for sale of Products to Third Parties in the Field and Territory, excluding transactions transferring a Product to a
Pieris Affiliate, Sublicensee, distributor and/or agent for resale, less the sum of the following items:

 

		(a)	customary trade, prompt payment, quantity or cash discounts to the extent actually allowed and
taken;

 

		(b)	amounts repaid or credited by reason of rejection, recalls or returns;

 

		(c)	to the extent separately stated on purchase orders, invoices or other documents of sale, any taxes,
duties, tariffs or other governmental charges levied on the production, sale, transportation, delivery or use of a Product;

 

		(d)	outbound transportation costs prepaid or allowed and costs of insurance of transit;

 

		(e)	discounts or rebates or other payments required by law to be made under Medicaid, Medicare or other
governmental special medical assistance programs to the extent actually allowed and taken; and

 

    Page 4 of 25

     

    

 

		(f)	amounts written off by reason of uncollectible bad debt, but not to exceed * of the Net Sales per
calendar year.

 

No other deductions shall be made
for commissions paid to individuals whether they be with independent sales agencies or regularly employed by Pieris and on its
payroll, or for the cost of collections. Products shall be considered “sold” ninety (90) days after billing or invoicing,
or upon receipt of payment, whichever comes first, provided, however, that Products are actually shipped to customers.

 

(2) for Sublicensees,
the net sales amounts reported to Pieris in accordance with the Sublicensee contractual terms and their then-currently used accounting
standards (provided, however, that such accounting standards are consistent with the US GAAP and/or IFRS or such other internationally
recognized accounting standards as may be agreed by the Parties).

 

Party. The term “Party” shall
mean Pieris or Enumeral, as the case may be, and “Parties” shall mean Pieris and Enumeral collectively.

 

Patent Rights. The term “Patent Rights”
shall mean all rights under any patent or patent application, in any country of the Territory, including any patents issuing on
such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination,
renewal, division, continuation or continuation-in-part to any of the foregoing.

 

Phase I Clinical Trial. The term “Phase
I Clinical Trial” means a human clinical trial for any Product in any country that would satisfy the requirements of 21 CFR
312.21(a).

 

Phase II Clinical Trial. The term “Phase
II Clinical Trial” means a human clinical trial conducted in any country that would satisfy the requirements of 21 CFR 312.21(b)
and is intended to explore one or more doses, dose response, and duration of effect, and to generate initial evidence of clinical
activity and safety, for any Product in the target patient population.

 

Phase III Clinical Trial. The term “Phase
III Clinical Trial” means a clinical trial in an extended human patient population designed to obtain data determining efficacy
and safety of any Product to support regulatory approvals in the proposed therapeutic indication, as more fully defined in 21 C.F.R.
§312.21(c), or its successor regulation, or the equivalent in any foreign country.

 

Product. The term “Product” means
a fusion protein, protein construct, or formulation comprising such fusion protein or protein construct, that incorporates all
or part of a First Antibody, Subsequent Antibody or Modification, wherein the First Antibody, Subsequent Antibody, or portion thereof
is fused with or linked to at least one Anticalin moiety. The term “Product” also includes such protein construct as
may further comprise one or more additional moieties; provided that at least one is an Anticalin moiety. The term “Product”
expressly includes bi-specific and multi-specific fusion proteins or protein constructs against at least two and up to an unlimited
number of targets.

 

    Page 5 of 25

     

    

 

Royalty Term. The term “Royalty Term”
shall mean, on a product-by-product and country-by-basis, the period of time commencing on the date of first commercial sale of
the Product in a given country and ending on the later of the date that is: (a) ten (10) years after the date of the first commercial
sale of the Product in such country; or (b) with respect to (i) the First Antibody, the expiration of the last to expire, to lapse,
or to be abandoned of any Valid Claim in the Patent Rights in the Enumeral IP that cover the manufacture, use, offer for sale,
sale or import of the Product that are filed as of the Effective Date, or that claim priority from the Patent Rights in the Enumeral
IP that cover the manufacture, use, offer for sale, sale or import of the Product that are filed as of the Effective Date, and
(ii) each Subsequent Antibody, the expiration of the last to expire, to lapse, or to be abandoned of any Valid Claim in the Patent
Rights in the Enumeral IP that cover the manufacture, use, offer for sale, sale or import of the Product that are filed as of the
Option Exercise Date for such Subsequent Antibody, or that claim priority from the Patent Rights in the Enumeral IP that cover
the manufacture, use, offer for sale, sale or import of the Product that are filed as of the Option Exercise Date for such Subsequent
Antibody.

 

Sublicensee. The term “Sublicensee”
shall mean an entity to which Pieris has licensed any right (through one or multiple tiers) pursuant to this Agreement.

 

Subsequent Antibody. The term “Subsequent
Antibody” or “Subsequent Antibodies” shall mean, individually or collectively the antibody or antibodies, and
all Modifications thereof, which principally and specifically bind(s) to one of the targets known as * and/or * as will be described
in Exhibit C that is or are licensed to Pieris pursuant to Section 4.7. To the extent that any Patent Rights in the Enumeral
IP include any claim(s) that relate to any antibody other than those listed in Exhibit C, the Subsequent Antibody or Subsequent
Antibodies shall be limited the particular antibody clones listed in Exhibit C, and any Modifications thereof. For avoidance
of doubt, any Subsequent Antibody includes any murine, chimeric and humanized versions of the antibody or the antibodies generated
through the Option Exercise Date.

 

Subsequent Antibody Option. The term “Subsequent
Antibody Option” shall have the meaning set forth in Section 4.7.

 

Territory. The term “Territory”
shall mean all countries of the world.

 

Term. The term “Term” shall have
the meaning set forth in Section 9.1.

 

Third Party. The term “Third Party”
shall mean any party other than Pieris or Enumeral.

 

Valid Claim. The term “Valid Claim”
means any claim of an issued and unexpired patent which claim has not been revoked or held unenforceable, unpatentable, or
invalid by a decision of a court or governmental agency of competent jurisdiction from which no further appeal can be taken or
has been taken within the time allowed for appeal, and has not been abandoned, disclaimed, denied or admitted to be invalid or
unenforceable through reissue or disclaimer (including through terminal disclaimer), and is not lost through an interference proceeding,
inter partes review, post-grant review proceeding or foreign equivalent, that is unappealable as a matter of right or unappealed
within the time allowed for appeal.

 

    Page 6 of 25

     

    

 

2. Grant of License, Transfer, and Exclusive Field 

 

2.1 License to Pieris. Subject to the terms
and conditions hereof, Enumeral hereby grants to Pieris during the Term a currently effective, royalty bearing, non-exclusive (except
as to the Exclusive Field) right and license (including the right to sublicense through multiple tiers pursuant to the terms and
conditions herein), under Enumeral IP, to research, have researched, develop, have developed, register, have registered, use, have
used, make, have made, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sold
and have sold Products in the Field and in the Territory. The license to Pieris includes the right to make Modifications to any
First Antibody and any Subsequent Antibody elected under Section 4.7.

 

2.2 Transfer. The Parties acknowledge that,
pursuant to Section 2.2 of the Original Agreement, Enumeral has provided sequence information and Know-How related to the First
Antibody. Within ten (10) days of the Option Exercise Date, Enumeral shall provide to Pieris any requested Know-How related to
any Subsequent Antibody generated by Enumeral through the Option Exercise Date. To the extent not already in the possession of
Pieris, this shall include all sequence information for any Subsequent Antibody, including any humanized or chimeric versions of
such antibody.

 

2.3 Exclusive Field. Until the completion
of all royalty payments under Section 4.5, Enumeral hereby covenants and agrees it shall not practice in the Exclusive Field. During
the Royalty Term, Enumeral shall not conduct any research or development activities in the Exclusive Field, file any patent applications
claiming any invention in the Exclusive Field, or assist any Third Party in doing so. Enumeral shall not out-license any Enumeral
IP to any Affiliate or Third Party for use in the Exclusive Field, and shall, if applicable, include in any out-license or other
agreement a restriction prohibiting the use of a First Antibody and/or Subsequent Antibody in the Exclusive Field. Enumeral shall
remain responsible for enforcement of this Section and shall be liable for any breach of this Section by any licensee or
sublicensee of Enumeral that violate this Section. Notwithstanding the foregoing, nothing herein shall be deemed to prevent any
Third Party from acquiring Enumeral, even if it is engaged in the research, development or sale of lipocalins, provided it does
not use lipocalins or lipocalin muteins with the First Antibody, Subsequent Antibody, or portion thereof in any research or development
efforts during the Term.

 

2.4 Sublicenses. Pieris shall have the right
to sublicense or subcontract (through multiple tiers) without the prior consent of Enumeral; provided, however, that in the event
of such sublicensing, (a) such Sublicensees will be subject to at least the same confidentiality and diligence obligations Pieris
has hereunder, and (b) Pieris will remain liable for all the terms and conditions of this Agreement and for any breach by the Sublicensee
of these terms, (c) Pieris promptly notifies Enumeral of any Sublicense along with the identity of the applicable Sublicensee(s),
and (d) all Sublicenses shall be in writing. Pieris shall not sublicense the First Antibody, any Subsequent Antibody or a Modification
unless it is part of a Product.

 

3. Diligence. 

 

3.1 Diligence. During the Term
of the Agreement, Pieris shall use Commercially Reasonable Efforts to develop at least one Product for sale in at least each of
the Major Markets.

 

4. Payments.

 

4.1 Initial Fee. The Parties
acknowledge that Pieris has paid to Enumeral an initial fee of $250,000 consistent with Section 4.1 of the Original Agreement.

 

    Page 7 of 25

     

    

 

4.2 Maintenance Fee. The Parties acknowledge
that Pieris has paid to Enumeral a maintenance fee of $750,000 on May 31, 2016 (“Maintenance Fee”).

 

4.3 Development Milestone Payments. With respect
to each of the First Antibody and the Subsequent Antibody, Pieris shall pay the following milestone payments to Enumeral by the
later of (i) * days of the occurrence of * Product (and * and * Product) to achieve each of the following events and (ii) * days
of the occurrence of the following events for any corresponding milestone payment with respect to any payment from Sublicensee
to Pieris:

 

	Development Event	 	* Product, 

* Indication	 	* Product or

Indication	 	* Product or

Indication
	‘Start of GLP Tox Studies	 	*	 	*	 	*
	Phase I Clinical Trial initiation (first in person dosing)	 	*	 	*	 	*
	Phase II Clinical Trial initiation (first in patient dosing)	 	*	 	

                                                                     

                                                                     

                                                                     

                                                                     

                                                                     

                                                                     

                                                                     

                                                                     

                                                                    *
	 	

                                                                     

                                                                     

                                                                     

                                                                     

                                                                     

                                                                     

                                                                     

                                                                     

                                                                    *

	Phase III Clinical Trial initiation 	 	*
	BLA filing US	 	*
	BLA or other marketing authorization filing EU	 	*
	BLA or other marketing authorization filing JP	 	*
	BLA or other marketing authorization approval US	 	*
	BLA or other marketing authorization approval EU	 	*
	BLA or other marketing authorization approval JP	 	*
	Total	 	*
	Grand Total	 	$37,750,000 (thirty seven million seven hundred and fifty thousand dollars)

 

    Page 8 of 25

     

    

 

In no event shall milestone payments paid by Pieris
under this Section 4.3 exceed $37,750,000 (thirty-seven million seven hundred and fifty thousand dollars) for the First Antibody
and $37,750,000 (thirty-seven million seven hundred and fifty thousand dollars) for the Subsequent Antibody.

 

4.4 Sales Milestone Payments. With respect
to each of the First Antibody and the Subsequent Antibody, Pieris shall pay the following sales milestone payments to Enumeral
by the later of (i) * days of the occurrence of * Product to achieve each of the following events and (ii) * days of the occurrence
of the following events for any corresponding milestone payment with respect to any payment from Sublicensee to Pieris:

 

	Net sales threshold	 	* Product	 	* Product
	1st year with Net Sales *	 	*	 	*
	1st year with Net Sales *	 	*	 	*
	1st year with Net Sales *	 	*	 	*
	Total	 	*	 	*
	Grand Total	 	$67,500,000 (sixty seven million five hundred thousand dollars)

 

In no event shall milestone payments paid by Pieris
under this Section 4.4 exceed $67,500,000 (sixty-seven million five hundred thousand dollars) for the First Antibody and $67,500,000
(sixty-seven million five hundred thousand dollars) for the Subsequent Antibody. Net Sales shall be calculated on a worldwide basis.

 

4.5 Royalty Payments. During the Royalty Term,
Pieris shall pay the following royalty payments to Enumeral within the time set forth in Section 5.2(b):

 

	Royalty Tier	 	Royalty Rate on incremental annual Net Sales
	* in Net Sales	 	*
	* in Net Sales	 	*
	* in Net Sales	 	*
	* in Net Sales	 	*

 

Royalty payments under this Section 4.5 shall be
incremental and calculated and paid on a Product-by-Product and on a worldwide basis. For avoidance of doubt, the Royalty Term
shall be on a country-by country basis and a royalty under this Section 4.5 shall not be paid for Net Sales in countries where
the Royalty Term has expired. After the Royalty Term has expired, on a country-by-country basis, the license granted to Pieris
under Section 2.1 shall be fully paid up, irrevocable, and royalty-free.

 

    Page 9 of 25

     

    

 

4.6 Royalty Payment Reduction.

 

4.6(a) In the event that it becomes necessary for
Pieris to enter into a license agreement, or other agreement, and pay a license fee or royalty to any Third Party due solely to
the inclusion of a First Antibody or Subsequent Antibody in a Product, the royalty payment described in Section 4.5 shall be reduced
by the amount of such Third Party payment, up to * of the royalty payment for each calendar year. For the avoidance of doubt, in
no event shall the royalty rate under Section 4.5 be reduced by more than * in any period.

 

4.6(b) In the event that no valid patent claim issues
from the Enumeral IP covering the First Antibody or Subsequent Antibody in a country or that all claims of the Enumeral IP covering
the First Antibody or Subsequent Antibody are subsequently invalidated in a country, then the royalty shall be reduced by fifty
percent (50%) for the duration of the Royalty Term on a country-by-country basis. For the avoidance of doubt, in no event shall
the royalty rate under Section 4.5 be reduced by more than fifty percent (50%) in any period.

 

4.7 Subsequent Antibody Option.

 

(a) Enumeral hereby grants to Pieris an exclusive
option, for a period ending on May 31, 2017, to license one or both Subsequent Antibodies in order to develop and commercialize
one or more additional Products within the Field (“Subsequent Antibody Option(s)”).

 

(b) To the extent that additional Know-How related
to a selected Subsequent Antibody is generated through May 31, 2017, then Enumeral shall provide Pieris with such Know-How upon
Pieris’ request prior to and through the Option Exercise Date. For avoidance of doubt, his includes full sequence information
for any humanized or chimeric versions of any Subsequent Antibody.

 

(c) If Pieris wishes to exercise one or two Subsequent
Antibody Options, Pieris shall provide written notice to Enumeral of its election to exercise the option during the period
commencing on the Effective Date and ending on May 31, 2017 (the “Option Period”). Exercise of a Subsequent
Antibody Option shall be by delivering to Enumeral written notice of Pieris’s election specifying the Subsequent Antibody(ies),
accompanied by the applicable payment amount(s) specified below. The date on which such written notice and related payment for
a Subsequent Antibody is received by Enumeral is referred to as an “Option Exercise Date.” For the avoidance
of doubt, Pieris may exercise the Subsequent Antibody Options separately and on different dates during the Option Period. If Pieris
exercises the Subsequent Antibody Option for one Subsequent Antibody, Pieris shall pay Enumeral *. If Pieris exercises the Subsequent
Antibody Option for the other Subsequent Antibody, Pieris shall pay Enumeral *. In the event that Pieris exercises the Subsequent
Antibody Options for both * and *, Pieris shall pay Enumeral an aggregate amount of *.

 

(d) Within * days of such payment(s) according
to Section 4.7(c), Enumeral shall provide to Pieris, to the extent not already in Pieris’ possession, Know-How Enumeral owns
or controls for any Subsequent Antibody useful or necessary for Pieris to develop and commercialize Products under this Agreement.
Such Know-How explicitly includes sequence information for any Subsequent Antibody. For avoidance of doubt, this further includes
all sequence information for any humanized or chimeric version of any Subsequent Antibody that may be generated in the ordinary
course of business through the applicable Option Exercise Date.

 

    Page 10 of 25

     

    

 

(e) Should Pieris exercise the Subsequent Antibody
Option(s), the license(s) to the Subsequent Antibod(ies) shall be effective as of the applicable Option Exercise Date.

 

(f) In the event that Pieris exercises the Subsequent
Antibody Option(s), this Agreement shall apply to the Subsequent Antibody(ies) mutatis mutandis as if the Subsequent Antibody(ies)
were a new First Antibody, meaning all terms shall apply to it or them in addition to the application of the terms to the First
Antibody.

 

(g) For the avoidance of doubt, Pieris is under no
obligation to exercise one or both Subsequent Antibody Option(s) or make the payment described in this Section 4.7. If Pieris does
not exercise the Subsequent Antibody Option(s), this Agreement shall continue to be effective.

 

4.8 Development and Commercialization. Pieris
shall be solely responsible for development and commercialization of all Products under this Agreement, and shall have no obligation
to consult with Enumeral regarding such development or commercialization activities.

 

5. Reports; Payments; Records. 

 

5.1 Reports and Payments.

 

(a) Reports. Within * days after the conclusion of
each Calendar Quarter commencing with the first Calendar Quarter in which Net Sales are generated, Pieris shall deliver to Enumeral
a report containing the following information (in each instance, on a Product-by-Product basis):

 

(i) the amount of Products sold, leased or otherwise
transferred or performed by Pieris, its Affiliates and Sublicensees for the applicable Calendar Quarter;

 

(ii) the gross amount billed or invoiced for Products
sold, leased or otherwise transferred or performed by Pieris, its Affiliates and Sublicensees during the applicable Calendar Quarter;

 

(iii) a calculation of Net Sales for the applicable
Calendar Quarter;

 

(iv) the total amount payable to Enumeral in U.S. Dollars
on Net Sales for the applicable Calendar Quarter, together with the exchange rates used for conversion.

 

Each such quarterly report shall be certified on
behalf of Pieris by its chief financial officer as true, correct and complete in all material respects. If no amounts are due to
Enumeral for a particular Calendar Quarter, the report shall so state. To the extent that any of the information described in this
Section 5.1(a) is not received from a Sublicensee, Pieris shall not be required to provide such information to Enumeral but shall
take actions to obtain such information.

 

(b) Payment. Within the later of (i) * days after
the end of each Calendar Quarter and (ii) * days after the end of each Quarter with respect to any payment from any Sublicensee,
Pieris shall pay Enumeral all amounts due with respect to Net Sales for the applicable Calendar Quarter.

 

    Page 11 of 25

     

    

 

5.2. Payment Currency. All payments due under
this Agreement will be paid in U.S. Dollars. Conversion of foreign currency to U.S. Dollars will be made at the conversion rate
existing in the United States (as reported in the Wall Street Journal) on the last working day of the applicable Calendar Quarter.
Such payments will be without deduction of exchange, collection or other charges.

 

5.3. Records. Pieris shall maintain, and shall,
if applicable, cause its Affiliates to maintain, complete and accurate records of Products that are sold, leased or transferred
under this Agreement, any amounts payable to Enumeral in relation to such Products, which records shall contain sufficient information
to permit Enumeral to confirm the accuracy of any reports or notifications delivered to Enumeral under Section 5.1. Pieris and
its Affiliates, as applicable, shall retain such records relating to a given Calendar Quarter for at least * years after the conclusion
of that Calendar Quarter, during which time Enumeral will have the right, at its expense, to cause an independent, certified public
accountant to inspect such records of Pieris during normal business hours for the purposes of verifying the accuracy of any reports
and payments delivered under this Agreement and Pieris’ compliance with the terms hereof. Such accountant or other auditor,
as applicable, shall not disclose to Enumeral any information other than information relating to the accuracy of reports and payments
delivered under this Agreement. The Parties shall reconcile any underpayment or overpayment within * days after the accountant
delivers the results of the audit. If any audit performed under this Section 5.3 reveals an underpayment in excess of * in any
calendar year, Pieris shall reimburse Enumeral for all amounts incurred in connection with such audit. For avoidance of doubt,
Enumeral shall not have the right to audit or inspect Sublicensee(s) directly but may audit or inspect any applicable materials
received from Sublicensee and in the possession of Pieris. Pieris, however, shall audit Sublicensees and require royalty and milestone
reports in connection with any Sublicense. Enumeral may exercise its rights under this Section 5.3 only once every 12-month period
and only with reasonable prior notice.

 

5.4. Late Payments. Any payments by Pieris
that are not paid on or before the date such payments are due under this Agreement will bear interest at * per month. Interest
will accrue beginning on the first day following the due date for payment and will be compounded quarterly. Payment of such interest
by Pieris shall not limit, in any way, Enumeral’s right to exercise any other remedies Enumeral may have as a consequence
of the lateness of any payment.

 

5.5. Payment Method. Each payment due to Enumeral
under this Agreement shall be paid by check or wire transfer of funds to Enumeral’s account in accordance with written instructions
provided by Enumeral. If made by wire transfer, such payments shall be marked so as to refer to this Agreement.

 

5.6. Withholding and Similar Taxes. Enumeral
will be responsible for and will pay all applicable taxes on all payments received from Pieris in connection with this Agreement.
If Pieris is required to withhold any amounts payable hereunder to Enumeral due to the applicable laws of any country, such amount
will be deducted from the payment to be made by Pieris and remitted to the appropriate taxing authority for the benefit of Enumeral.
Pieris will withhold only such amounts as are required to be withheld by applicable law in the country from which payment is being
made. Pieris shall submit to Enumeral originals of the remittance voucher and the official receipt evidencing the payment of the
corresponding taxes with the applicable royalty report. Pieris will cooperate with Enumeral to provide such information and records
as Enumeral may require in connection with any application by Enumeral to the tax authorities in any country, including attempt
to obtain an exemption or a credit for any withholding tax paid in any country.

 

    Page 12 of 25

     

    

 

6. Intellectual Property.

 

6.1 Product Intellectual Property. Pieris
shall have the right to file patent applications on inventions developed by, at the direction of, or under the sponsorship of Pieris
(including but not limited to inventions conceived by Pieris employees, contractors, consultants, and/or Sublicenses) related to
any Product, materials, processes or other intellectual property generated under this Agreement including any methods of manufacture,
methods of use, or formulations thereof (“Developed IP”). Developed IP includes but is not limited to intellectual
property directed to the sequence for any Product, Modifications of the First Antibody and any Subsequent Antibody elected under
Section 4.7, and formulations, methods of use, and methods of manufacture thereof. In the event of termination of this Agreement,
Pieris shall continue to own such intellectual property.

 

7. Liability and Indemnification. 

 

7.1 Indemnity by Enumeral. Enumeral shall indemnify,
defend and hold harmless Pieris, its Affiliates, their respective directors, officers, employees and agents, and their respective
successors, heirs and assigns (collectively, the “Pieris Indemnitees”) from and against all liabilities, damages, losses
and expenses (including reasonable attorneys’ fees and expenses of litigation) (collectively, “Losses”) (i) incurred
by or imposed upon the Pieris Indemnitees, or any of them, as a result of any claim by the Massachusetts Institute of Technology
(“MIT”), Whitehead Institute for Biomedical Research, the General Hospital Corporation (d/b/a Massachusetts General
Hospital), the President and Fellows of Harvard College, and Howard Hughes Medical Institute (collectively the “MIT Agreement
Parties”) in connection with any agreement between the MIT Agreement Parties and Enumeral, or (ii) incurred by or imposed
upon any Pieris Indemnitees, as a direct result of claims, suits, actions, demands by, or judgments in favor of, Third Parties
arising out of or resulting from a breach of the representations and warranties hereunder (collectively, the “Pieris Indemnity
Claims”).

 

7.2 Indemnity by Pieris. Pieris shall indemnify,
defend and hold harmless Enumeral, its Affiliates, their respective directors, officers, employees and agents, and their respective
successors, heirs and assigns (collectively, the “Enumeral Indemnitees”) against any Losses incurred by or imposed
upon any Enumeral Indemnitees, as a direct result of claims, suits, actions, demands by, or judgments in favor of, Third Parties
arising out of or resulting from (i) the development, commercialization, manufacture or use of any Product either before or after
the receipt of any Marketing Authorization or (ii) any breach of the representations and warranties hereunder (collectively, the
“Enumeral Indemnity Claims”).

 

    Page 13 of 25

     

    

 

7.3 Conditions for Indemnification. A Person
seeking recovery under this Section 7 (the “Indemnified Party”) in respect of a Claim shall give prompt notice of such
Claim to the Party from whom indemnification is sought (the “Indemnifying Party”); and provided that the Indemnifying
Party is not contesting its obligation under this Section 7, shall permit the Indemnifying Party to control any litigation relating
to such Claim and the disposition of such Claim; and further provided, that the Indemnifying Party shall (a) act reasonably and
in good faith with respect to all matters relating to the settlement or disposition of such Claim as the settlement or disposition
relates to such Indemnified Party and (b) not settle or otherwise resolve such claim without the prior written consent of such
Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). Each Indemnified Party shall cooperate
with the Indemnifying Party in its defense of any such Claim in all reasonable respects and shall have the right to be present
in person or through counsel at all legal proceedings with respect to such Claim. If the Indemnifying Party does not assume and
conduct the defense of the Claim as provided above, (a) the Indemnified Party may defend against, consent to the entry of any judgment,
or enter into any settlement with respect to such Claim in any manner the Indemnified Party may deem reasonably appropriate (and
the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (b)
the Indemnifying Party shall remain responsible to indemnify the Indemnified Party as provided in this Section 7.

 

7.4 Insurance. Each Party shall procure and
maintain insurance, including, as applicable to Pieris and any of its Affiliates, product liability insurance, or shall self-insure,
in each case in a manner adequate to cover its obligations under this Agreement and consistent with normal business practices of
prudent companies similarly situated at all times during the Term and for a period of five (5) years thereafter. Each Party shall
procure insurance or self-insure at its own expense. It is understood that such insurance shall not be construed to create a limit
of either Party’s liability with respect to its indemnification obligations under this Section 7. Each Party shall provide
the other Party with written evidence of such insurance or self-insurance upon request. Each Party shall provide the other Party
with prompt written notice prior to the cancellation, non-renewal or material change in such insurance.

 

8. Confidentiality. 

 

8.1 Treatment of Confidential Information.
With respect to Confidential Information of Discloser, Recipient agrees to: (a) use such Confidential Information solely as contemplated
by this Agreement (including by Pieris for the development and commercialization of one or more Products) and for no other purpose;
(b) hold such Confidential Information in confidence and not to disclose such Confidential Information to others, except to its
employees, consultants and representatives who require Confidential Information in order to carry out the Purpose and who are subject
to binding obligations of confidentiality and restricted use at least as protective as those of this Agreement; (c) protect the
confidentiality of such Confidential Information using at least the same level of efforts and measures used to protect its own
valuable confidential information, and at least commercially reasonable efforts and measures; and (d) notify Discloser as promptly
as practicable of any unauthorized use or disclosure of such Confidential Information of which Recipient becomes aware.

 

    Page 14 of 25

     

    

 

8.2 Exceptions to Confidential Treatment.
The obligations of Section 8.1 shall not apply to any Confidential Information that: (a) Recipient knew before learning it under
this Agreement, as demonstrated by written records predating the date it was learned under this Agreement; (b) is now, or becomes
in the future, publicly available except by an act or omission of Recipient; (c) a Third Party discloses to Recipient without any
restriction on disclosure or breach of confidentiality obligations to which such Third Party is subject; or (d) Recipient independently
develops without use of or reference to Confidential Information, as demonstrated by Recipient’s written records contemporaneous
with such development.

 

8.3 Required Disclosures. Notwithstanding
Section 8.1, Recipient may disclose Discloser’s Confidential Information to the extent and to the persons or entities required
under applicable governmental law, rule, regulation or order provided that Recipient (a) first gives prompt written notice of such
disclosure requirement to Discloser so as to enable Discloser to seek any limitations on or exemptions from such disclosure requirement
and (b) reasonably cooperates at Discloser’s request in any such efforts by Discloser.

 

8.4 Ownership of Confidential Information.
Subject to Section 8.6, Discloser retains all right, title and interest in and to its Confidential Information.

 

8.5 Publicity. Under the terms and conditions
of the Original Agreement, the parties have filed Form 8-K statements and Enumeral has issued a press release. The Parties shall
agree on the content of each Party’s respective Form 8-K statements and an Enumeral Press Release in connection with this
Agreement prior to the filing or disclosure of such statements and press release. No disclosure of the existence, or the terms,
of this Agreement or the Original Agreement may be made by either Party, and no Party shall use the name, trademark, trade name
or logo of the other Party or its employees in any publicity, promotion, news release or disclosure relating to this Agreement
or the Original Agreement or their subject matter, without the prior express written permission of the other Party, except as otherwise
set forth herein and/or to the extent as may be required by law or regulation (including, but not limited to, federal and state
securities laws), for which prior written permission is not required. With respect to any filing of this Agreement with the U.S.
Securities and Exchange Commission, each Party will provide the other Party with reasonable advance notice and a copy of the portion
of such proposed filing to which the Agreement directly relates. Each Party may provide comments and/or requests regarding any
proposed confidential treatment of the Agreement or the terms and conditions of the Agreement, as the case may be, and the other
Party will consider any reasonable comments and requests made with respect to such filing, provided that such comments and requests
are consistent with applicable law and regulation. The Parties will agree to propose redaction of the same information on any confidential
treatment application for this Agreement and the Original Agreement. Notwithstanding this Section 8.5, each Party shall be permitted
to issue, at a later date, public filings, presentations and press releases regarding this Agreement or the Original Agreement
that contain information from the Parties’ Form 8-K statements attached as Exhibit D to the Original Agreement, the Enumeral
press release attached as Exhibit E to the Original Agreement, and the Form 8-K statements and Enumeral press release agreed to
by the Parties in connection with this Agreement.

 

    Page 15 of 25

     

    

 

8.6 Ownership of Information and Data. All
information generated by Pieris using Enumeral Confidential Information that is related to the Product shall be the sole property
of Pieris and Pieris shall have the unlimited right to use and disclose such information. All information related to the Product,
whether generated using Enumeral Confidential Information or otherwise, shall be the sole property of Pieris. Pieris shall have
no obligation to disclose the information described in this Section 8.6 to Enumeral.

 

8.7 Third Party Disclosure. Notwithstanding
anything in this Section 8, either Party may share the existence and terms of this Agreement, the Original Agreement, and Enumeral
Confidential Information related to the First Antibody and, if applicable, Subsequent Antibody with Third Parties under an obligation
of confidentiality at least as restrictive as those of this Agreement and the CDA (as defined below) without the prior consent
of the other Party. This includes the right to provide such information to potential investors in order to facilitate investment
financing in connection with the development of one or more Products by Pieris. In all events, each Party remains subject to its
obligations set forth herein and in the CDA.

 

8.8 Prior Agreements. The parties have previously
entered into a Mutual Confidential Disclosure Agreement, dated October 9, 2015 (the “CDA”), a Material Transfer and
Non-Disclosure Agreement, dated January 27, 2016 (the “MTA”), and the Original Agreement. Confidential Information
under this Agreement includes all non-public information disclosed in connection with the CDA, the MTA, or the Original Agreement.
To the extent that there are any inconsistencies, this Agreement supersedes the CDA, and the MTA. Further, this Agreement replaces
and supersedes the Original Agreement.

 

9. Term and Termination. 

 

9.1 Term. The Term of this Agreement shall
be from the Effective Date and, in the absence of early termination as provided for below, shall expire upon the expiration of
the last to expire patent in the Enumeral IP.

 

9.2 Termination by Pieris. Pieris may terminate
this Agreement at any time upon thirty (30) days’ notice.

 

9.3 Termination by Enumeral. Enumeral may
terminate this Agreement if Pieris breaches any of its material obligations under this Agreement and fails to cure such breach
within sixty (60) days (or thirty (30) days with respect to a breach of payment obligations by Pieris) following its receipt of
written notice thereof from Enumeral if such breach is curable within the aforesaid period; provided, however, that,
without limiting the application of Section 12.3 to this Agreement, if there is a dispute between the Parties in connection with
such termination under this Section 9.3 shall be subject to the dispute resolution procedures of Section 12.3.

 

    Page 16 of 25

     

    

 

9.4 Termination for Insolvency. A Party shall
have the right to terminate this Agreement in its entirety upon immediate written notice if the other Party (i) applies for or
consents to the appointment of, or the taking of possession by, a receiver, custodian, trustee or liquidator of itself or of all
of a substantial part of its property, (ii) makes a general assignment for the benefit of its creditors, (iii) commences a voluntary
case under the Bankruptcy Code (as defined below) of any country, (iv) fails to controvert in a timely and appropriate manner,
or acquiesce in writing to, any petition filed against it in any involuntary case under the Bankruptcy Code of any country, (v)
takes a corporate action for the purpose of effecting any of the foregoing, or (vi) has an order for relief against it entered
in an involuntary case under the Bankruptcy Code of any country and, in any of (i) through (v) above, the application, assignment,
commencement, filing, or corporate action continues unstayed for, and/or is not otherwise discharged or withdrawn on or before,
a period of sixty (60) days.

 

9.5 Effect of Termination. In the event of
a termination of this Agreement, Pieris may retain and shall not be required to provide Enumeral with information or materials
related to any Products created or developed in connection with this Agreement, including the material described in Section 8.6.

 

9.6 Survival. The following Sections shall
survive termination or expiration of this Agreement:1, 4 (to the extent any payments are or will be earned as of or after termination),
5 (to the extent any payments are or will be earned as of or after termination), 6.1, 7, 8, 9, 10, 12.2, 12.3, 12.4, 12.5, 12.6,
12.7 and 12.9.

 

10. Representations and Warranties. 

 

10.1 No Notice of Infringement. Enumeral warrants
and represents that it has not received a cease and desist letter or otherwise been informed by a Third Party that it may be infringing
intellectual property related to the First Antibody or Subsequent Antibody or that would otherwise adversely impair Pieris’
ability to develop and commercialize Products under this Agreement.

 

10.2 No Conflicting Obligation. Enumeral warrants
and represents that it has the ability to enter into this Agreement and that no agreement with any Third Party, including MIT,
conflicts with this Agreement.

 

10.3 Mutual Representations and Warranties.
Pieris and Enumeral each represents and warrants to the other, as of the Effective Date (except as otherwise noted), as follows:

 

(a) Organization. It is a corporation or company
duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, and has all requisite
power and authority, corporate or otherwise, to execute, deliver and perform this Agreement.

 

(b) Authorization. The execution and delivery
of this Agreement and the performance by it of the transactions contemplated hereby have been duly authorized by all necessary
corporate or company action and will not violate (a) such Party’s certificate of incorporation or bylaws (or equivalent organizational
documents), (b) any agreement, instrument or contractual obligation to which such Party is bound in any material respect, (c) any
requirement of any applicable laws, or (d) any order, writ, judgment, injunction, decree, determination or award of any court or
governmental agency presently in effect applicable to such Party.

 

(c) Binding Agreement. This Agreement is a
legal, valid and binding obligation of such Party, enforceable against it in accordance with its terms and conditions.

 

    Page 17 of 25

     

    

 

(d) No Inconsistent Obligation. It is not
under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any respect with the terms
of this Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder.

 

(e) Compliance with Law. During the Term,
it will comply, and will ensure that its Affiliates comply, with all local, state, federal and international laws and regulations
in all material respects in connection with its obligations hereunder, including, with respect to Pieris, those laws and regulations
relating to the development, manufacture, use, sale and importation of Products.

 

11. Patent Prosecution and Enforcement

 

11.1 Prosecution. It is the intent of the Parties
to pursue Patent Rights within the Enumeral IP collaboratively to provide patent protection for the Products. In each country where
patent protection is sought, Enumeral shall make a good faith effort to obtain claims adequate to provide patent protection for
the First Antibody and any Subsequent Antibody moiety of the Products. Enumeral shall provide copies of all patent applications,
office actions and draft responses, proposed claims, and other substantive filings to Pieris with sufficient time for Pieris to
review and provide comments to Enumeral related to the First Antibody and any Subsequent Antibody licensed hereunder in the Field
but only as it relates to a Product. Enumeral shall give good faith consideration to Pieris’ comments and proposed claim
amendments or additions.

 

11.2 Prosecution Costs. Enumeral shall be responsible
for all costs associated with the filing, prosecution and maintenance of the Patent Rights within the Enumeral IP.

 

11.3 Third Party Infringement.

 

(a) General.

 

(i)          Notice. During the
Term, each Party shall promptly report in writing to the other Party any known or suspected infringement of any Enumeral IP, or
any unauthorized use or misappropriation of any Enumeral Know-How (each, an “Infringement”), of which such Party becomes
aware, and shall provide the other Party with all available evidence supporting such knowledge or suspicion.

 

    Page 18 of 25

     

    

 

(ii)           Right to Enforce.
Enumeral shall have the right, but not the obligation, to address such known or suspected infringement or misappropriation of the
Enumeral IP licensed hereunder by taking reasonable enforcement action, including warning letters, legal proceedings, and settlement,
provided that Enumeral shall take no steps to address such known or suspected infringement or misappropriation of the Enumeral
IP licensed hereunder to the extent that the infringement or misappropriation relates to a Product in any way, including in the
event of a biosimilar or follow-on-biologic product or any drug or composition that includes an Anticalin, without the prior written
consent of Pieris. Enumeral shall keep Pieris fully informed about such enforcement action, and Pieris shall provide all reasonable
cooperation to Enumeral. Pieris agrees to join any action as a party to the extent necessary in any litigation. Enumeral shall
not take any position with respect to, or compromise or settle, any such Infringement in a way that is reasonably likely to directly
and adversely affect the scope, validity or enforceability of any Enumeral IP, without the prior written consent of Pieris, which
consent shall not be unreasonably withheld. If Enumeral does not intend to undertake enforcement action in response to an Infringement
of Enumeral IP, or ceases to diligently pursue an enforcement action with respect to an Infringement, it shall promptly inform
Pieris. All costs, including attorneys’ fees, relating to enforcement action under this Section 11.3(a)(ii) shall be borne
solely by Enumeral.

 

(iii)         Cooperation. Pieris
shall have the right to participate in and to be represented by counsel of its choice, in an enforcement action that involves Enumeral
IP and relates to a Product under Section 11.3(a)(ii). Enumeral agrees to keep Pieris informed concerning any such enforcement
action, to consult with Pieris concerning litigation strategy, and to give good faith consideration to Pieris’s comments
and requests concerning such action. In all such enforcement actions, the Parties shall cooperate with and assist each other in
all reasonable respects.

 

(b)           Allocation of Proceeds. In any enforcement
action that involves Enumeral IP and relates to a Product under Section 11.3(a)(ii), the proceeds (whether in the form of damages
or payout from a settlement) first shall be allocated toward reimbursement of costs and expenses incurred by Enumeral pursuant
to Section 11.3(a)(i), and then toward reimbursement of costs and expenses incurred by Pieris. Thereafter, Enumeral shall be entitled
to * and Pieris shall be entitled to * of the remaining proceeds.

 

11.4 Defense of Third Party Claims. If the
manufacture, use, offer for sale, sale or import of any Product becomes the subject of a third party claim or assertion of misappropriation
of Know-How or infringement of third party Patent Rights, the Party first having notice of the claim or assertion shall notify
the other Party promptly, and the Parties shall confer to consider an appropriate course of action. Pieris shall have the right
to defend itself in any lawsuit that names it as a defendant, at Pieris’ expense and with Pieris controlling selection of
counsel. To the extent that Enumeral is named as a co-defendant, Enumeral shall have the right to participate with counsel of its
choice, at Enumeral’s expense. Neither Party shall enter into any settlement of any claim described in this Section 11.4
that affects the other Party’s rights or interests, without such other Party’s written consent, which consent shall
not be unreasonably withheld or delayed. In any event, the Parties shall reasonably assist one another and cooperate in such litigation.

 

    Page 19 of 25

     

    

 

12. Miscellaneous.

 

12.1 Bankruptcy. All licenses (and to the
extent applicable rights) granted under or pursuant to this Agreement by Enumeral to Pieris are, and shall be deemed to be, for
purposes of Section 365(n) of Title 11, United States Code (the “Bankruptcy Code”) licenses of rights to “intellectual
property” as defined under Section 101 of the Bankruptcy Code. The Parties agree that Pieris, as a licensee of such rights
under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code.

 

12.2 Limitation on Damages. Other than the
representations and warranties set forth herein, Pieris and Enumeral disclaim all other warranties, whether express or implied,
with respect to each of their obligations hereunder, including whether one or more Products can be successfully developed or marketed.
In no event shall either Pieris or Enumeral be liable for special, indirect, incidental or consequential damages arising out of
this Agreement based on contract, tort or any other legal theory.

 

12.3 Dispute Resolution. In the event of any
controversy, claim or counterclaim arising out of or in relation to this Agreement, the Parties will first attempt to resolve such
controversy or claim through good-faith negotiation between Pieris’ CEO and Enumeral’s CEO, for a period of not less
than thirty (30) days following written notification of such controversy or claim to the other Party. If such controversy or claim
cannot be resolved by means of such negotiations during such period, then it will be finally settled under the Rules of Arbitration
of the International Chamber of Commerce by one or more arbitrators appointed in accordance with such rules. The place of arbitration
will be New York, the language to be used in the arbitration proceedings will be English. Notwithstanding the foregoing, nothing
shall prevent either Party from seeking injunctive or other similar equitable relief in in the venue permitted by Section 12.4.

 

12.4 Governing Law. This Agreement shall be
governed by and construed in accordance with the laws of New York, without reference to its conflict of laws principles. Subject
to Section 12.3, the Parties consent to the exclusive jurisdiction of the state and federal courts of New York in the event that
there is a dispute related to this Agreement.

 

12.5 Assignment. This Agreement may not be
assigned or transferred by either Party without the prior written consent of the other Party. Notwithstanding the foregoing, either
Party shall have the right to assign this Agreement to its Affiliates or to a Third Party in connection with: (i) an acquisition
(of or by), a consolidation with, or merger into, any other corporation or other entity or person; (ii) any corporate reorganization
wherein there is a change of control; or (iii) the sale of its assets to which this Agreement relates; provided, however, that
in any such transaction the assignee expressly obligates itself in a written instrument delivered to the non-assigning Party to
this Agreement, on or before the date of closing of such transaction, to fully perform all of the obligations of the assigning
Party under this Agreement.  This right of assignment shall likewise be available to the assignee in the same manner as it
is to the assigning Party, and subsequent assignees in like manner, provided that in each instance of assignment, the assignee
provides the writing specified above to the non-assigning Party to this Agreement prior to the date of closing of such transaction.

 

12.6 Entire Understanding. This Agreement
contains the entire understanding between the Parties hereto with respect to the within subject matter and supersedes any and all
prior agreements, understandings and arrangements, whether written or oral.

 

    Page 20 of 25

     

    

 

12.7 Unenforceable Provisions and Severability.
If any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall
be replaced by valid and enforceable provisions that will achieve as far as possible the economic business intentions of the Parties.
However, the remainder of this Agreement will remain in full force and effect, provided that the material interests of the Parties
are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions.

 

12.8 Waiver and Amendment. This Agreement
may be amended, modified, superseded or canceled, and any of the terms of this Agreement may be waived, only by a written instrument
executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The delay or failure of either Party
at any time or times to require performance or to exercise any right arising out of any provisions shall in no manner affect the
rights at a later time to enforce the same. Any waiver by a party of a particular provision or right shall be in writing, shall
be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such party. No single or
partial exercise of any right, power or privilege will preclude any other or further exercise of such right, power or privilege
or the exercise of any other right, power or privilege. No waiver by either Party of any condition or of the breach of any term
contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered
as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. Except
as expressly set forth in this Agreement, all rights and remedies available to a party, whether under this Agreement or afforded
by applicable laws or otherwise, will be cumulative and not in the alternative to any other rights or remedies that may be available
to such party.

 

12.9 Non-Use of Names. Pieris shall not use
the name of “Massachusetts Institute of Technology,” “Lincoln Laboratory”, the “Whitehead Institute
for Biomedical Research”, “Harvard University”, “Massachusetts General Hospital” or any variation,
adaptation, or abbreviation thereof, or of any of its trustees, directors, officers, faculty, students, employees, or agents, or
any trademark owned by MIT, the Whitehead Institute for Biomedical Research, Harvard University, and Massachusetts General Hospital,
in any advertising, promotional or sales material or other public announcement or disclosure, including any document employed to
obtain funds or financing related to this Agreement.

 

    Page 21 of 25

     

    

 

In Witness Whereof, the Parties hereto
have executed this Agreement as of the Effective Date.

 

	Pieris Pharmaceuticals Inc.	 	Enumeral Biomedical Holdings Inc.
	 	 	 	 	 
	By:	/s/ Stephen Yoder	 	By:	/s/ John J. Rydzewski
	 	 	 	 	 
	Name:	Stephen Yoder	 	Name:	John J. Rydzewski
	 	 	 	 	 
	Title:	President and CEO	 	Title:	Executive Chairman
	 	 	 	 	 
	Date: June 6, 2016	 	Date: June 6, 2016
	 	 	 	 	 
	Pieris Pharmaceuticals GmbH
	 	 	 	 	 
	By:	
        /s/ Stephen Yoder 
	 	 	 
	 	 	 	 	 
	Name:	Stephen Yoder	 	 	 
	 	 	 	 	 
	Title:	President and CEO	 	 	 
	 	 	 	 	 
	Date: June 6, 2016	 	 	 

 

    Page 22 of 25

     

    

 

Exhibit A

 

Patent Rights as of the Effective Date

 

The subject matter that pertains to the First Antibody and the
Subsequent Antibodies (but not subject matter that would apply to a different antibody) in the following patent applications:

 

	Patent Application No.	 	Filing Date

 

*

 

    Page 23 of 25

     

    

 

Exhibit B

 

First Antibody Description

 

*

 

    Page 24 of 25

     

    

 

Exhibit C

 

Subsequent Antibody Descriptions

 

Enumeral antibodies against * and *, including humanized or
chimeric sequences and other Know-How generated through the Option Exercise Date, to be described with specificity, in the event
that one or both Subsequent Antibody Options are exercised.

 

    Page 25 of 25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]